`
`INO Therapeutics LLC
`
`By:
`
`Dominick A. Conde
`dconde@fchs.com
`(212) 218-2100
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`Praxair Distribution, Inc.
`Petitioner,
`v.
`INO Therapeutics LLC
`Patent Owner.
`________________
`
`Case IPR2015-00526
`U.S. Patent No. 8,795,741
`________________
`
`
`
`PATENT OWNER’S EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-00526
`U.S. Patent No. 8,795,741
`
`
`EXHIBIT LIST
`
`Pursuant to 37 C.F.R. § 42.63(e), Patent Owner INO Therapeutics LLC
`
`(“Ikaria”) respectfully submits the following current exhibit list.
`
`
`
`Ikaria Exhibit No.
`
`Description
`
`2001 Reserved
`
`2002 Reserved
`
`2003 Adatia et al, “Inhaled nitric oxide and hemodynamic
`
`evaluation of patients with pulmonary hypertension
`
`before transplantation,” 25:1656-64, J. Am. Coll.
`
`Cardiol., 1995 (“Adatia”)
`
`
`
`2004 Beghetti et al., “Inhaled nitric oxide can cause severe
`
`systemic hypotension,” 130:844, J. Pediatr., 1997
`
`(“Beghetti (1997)”)
`
`
`
`2005 Rosales et al., “Adverse hemodynamic effects observed
`
`with inhaled nitric oxide after surgical repair of total
`
`anomalous pulmonary venous return,” 20:224-26,
`
`Pediatr. Cardiol., 1999 (“Rosales”)
`
`2
`
`
`
`
`
`Ikaria Exhibit No.
`
`
`
`
`
`Case IPR2015-00526
`U.S. Patent No. 8,795,741
`Description
`
`2006 Lipshultz, “Ventricular dysfunction clinical research in
`
`infants, children and adolescents,” 12:1-28, Prog.
`
`Pediatr. Cardiol., 2000 (“Lipshultz”)
`
`2007 Stedman’s Medical Dictionary at a Glance, 28th Ed,
`
`Lippincott Williams & Wilkins ©2006, pg. 359
`
`(“Stedman’s 2006”)
`
`2008 Webster’s II New College Dictionary, Houghton Mifflin
`
`Company, ©1995, pg. 194 (“Webster 1995”)
`
`2009 Gidding, “The Importance of Randomized Controlled
`
`Trials in Pediatric Cardiology,” 298:1214-1216, JAMA.
`
`2007 (“Gidding”)
`
`2010 Balaguru et al., “Management of Heart Failure in
`
`Children,” 30:5-30, Curr. Probl. Pediatr., 2000
`
`(“Balaguru”)
`
`2011 Berger et al., “Clinical features of paediatric pulmonary
`
`hypertension: a registry study,” 379:537-46, Lancet,
`
`2012 (“Berger”)
`
`
`
`3
`
`
`
`
`
`Ikaria Exhibit No.
`
`
`
`
`
`Case IPR2015-00526
`U.S. Patent No. 8,795,741
`Description
`
`2012 Rimensberger et al., “Inhaled nitric oxide versus
`
`aerosolized iloprost in secondary pulmonary
`
`hypertension in children with congenital heart disease:
`
`vasodilator capacity and cellular mechanisms”, 103:
`
`544-48, Circulation, 2001 (“Rimensberger”)
`
`
`
`May 6, 2015
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`
`
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-00526
`U.S. Patent No. 8,795,741
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e)(4), I certify that a copy of the foregoing
`
`PATENT OWNER’S EXHIBIT LIST was served on May 6, 2015 by causing it to
`
`be sent by email to counsel for Petitioner at the following email addresses:
`
`sanjay.murthy@klgates.com
`
`sara.kerrane@klgates.com
`
`michael.abernathy@klgates.com
`
`May 6, 2015
`
`Respectfully submitted,
`
`
`
` /Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`
`5